Drug intelligence / Profile preview

alpha 2 integrin shRNA

Development stage
Preclinical
Lead developer
AntiCancer
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

alpha 2 integrin shRNA is a gene-silencing tool designed to reduce the expression of the alpha 2 integrin subunit (ITGA2). Integrin alpha 2 dimerizes with the beta 1 subunit to form the α2β1 heterodimer, which serves as a major cell surface receptor for collagen and plays a critical role in cell adhesion, migration, and tumor progression. In preclinical research, specifically in pancreatic cancer models, lentiviral-based delivery of this shRNA has been shown to significantly inhibit cancer cell adhesion and proliferation on collagen types I and IV. Although it demonstrates potent knockdown of ITGA2 mRNA and protein levels (often exceeding 90%), studies indicate that targeting the alpha 2 subunit may be less effective at inhibiting in vivo tumor growth and metastasis compared to targeting the beta 1 subunit, which appears to play a more central role in pancreatic cancer malignancy.

Other names
ITGA2 shRNAITGA-2 shRNAITGA 2 shRNAintegrin alpha 2 shRNAalpha 2 subunit shRNAalpha2 subunit shRNAalpha-2 subunit shRNA
02

Targets

Integrin subunit alpha 2 (ITGA2) mRNA

Beyond the preview

Go deeper on alpha 2 integrin shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha 2 integrin shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call